Clinical trials: sponsored by Boehringer Ingelheim
Sleep Initiation and Maintenance Disorders
Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.
To investigate the efficacy and safety of Brotizolam in the treatment of patients with insomnia in comparison with that of Estazolam
- Trial name
- NCT00347295
- Testing
- Brotizolam, Estazolam
- Where
- 8 sites in China
- Volunteers
- 253 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg
To demonstrate that a fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg is superior to telmisartan 80 mg alone in patients, who fail to respond adequately to telmisartan 80 mg monotherapy, in lowering seated trough…
- Trial name
- NCT00146341
- Testing
- Telmisartan/HCTZ, Telmisartan
- Where
- 9 sites in China
- Volunteers
- 345 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus
Study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg) administered orally once daily for 28 days in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT02183324
- Testing
- Low dose of BI 1356 BS, Medium dose of BI 1356 BS, High dose of BI 1356 BS
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Colic
Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort
Study to determine whether hyoscine butylbromide can provide adequate symptomatic relief of a single episode - defined as lasting not longer than 1 day - and multiple episodes of abdominal pain or discomfort associated with…
- Trial name
- NCT02242292
- Testing
- Hyoscine butylbromide
- Volunteers
- 527 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Dose Finding Study in COPD
The primary objective of this study is to determine the optimum dose of BEA 2180 BR inhalation solut ion delivered by the Respimat ? inhaler once daily for four weeks in patients with COPD.
- Trial name
- NCT00122434
- Testing
- BEA 2180 BR, tiotropium
- Where
- 43 sites in United States, Belgium and 1 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
The objective of this trial is to assess the safety and efficacy of 52 weeks of open-label treatment with the fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg and telmisartan 40 mg plus HCTZ 12.5 mg in patients with…
- Trial name
- NCT00326768
- Testing
- Telmisartan 40 mg/HCTZ 12.5 mg, Telmisartan 40 mg, Telmisartan 80 mg/HCTZ 12.5 mg
- Where
- 3 sites in Japan
- Volunteers
- 184 people
- Sponsor
- Boehringer Ingelheim
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer
The overall purpose of this phase II trial was to evaluate the efficacy of 250 mg BIBF 1120 twice daily (BID) versus 150 mg BIBF 1120 BID in patients with advanced non-small-cell lung cancer (NSCLC) who had failed at least one…
- Trial name
- NCT02182050
- Testing
- BIBF 1120 ES low dose, BIBF 1120 ES high dose
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg [Micardis HCT] to valsartan 160 mg / hydrochlorothiazide 25 mg [Diovan HCT] and placebo in the treatment of…
- Trial name
- NCT00168779
- Testing
- telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg
- Where
- 113 sites in United States
- Volunteers
- 1,185 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
- Trial name
- NCT00281593
- Testing
- Telmisartan, Ramipril
- Where
- 119 sites in United States, Argentina and 4 more
- Volunteers
- 1,354 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma
- Trial name
- NCT00152984
- Testing
- Tiotropium inhalation capsules
- Where
- 68 sites in Belgium, Canada and 6 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Pharyngitis
Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis
The purpose of this trial is to investigate efficacy and tolerability of lozenges containing 20 mg a mbroxol hydrochloride (Mucoangin?) relative to lozenges containing placebo and lozenges containing 3 mg benzocaine in relieving…
- Trial name
- NCT00148499
- Testing
- Ambroxol hydrochloride (Mucoangin?), benzocaine
- Where
- 14 sites in Romania, Ukraine
- Volunteers
- 751 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension
Study to assess the blood pressure lowering effects of two doses of telmisartan over a four-week treatment period; to determine potentially effective doses for pediatric patients for future studies; to assess the safety and…
- Trial name
- NCT02242344
- Testing
- Telmisartan
- Volunteers
- 77 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients
The objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive…
- Trial name
- NCT00157235
- Testing
- Tiotropium bromide
- Where
- 12 sites in Italy
- Volunteers
- 234 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
The primary objective of this trial is to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood pressure after eight weeks compared with a fixed dose…
- Trial name
- NCT00239369
- Testing
- Fixed dose combination telmisartan 80 mg + HCTZ 25 mg, Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg
- Where
- 84 sites in Denmark, Finland and 14 more
- Volunteers
- 713 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe
This is a descriptive, observational, multi-country European cross-sectional study of new users of dabigatran etexilate that aims to characterise on- and off-label status and other medical characteristics at the time of the first…
- Trial name
- NCT02240654
- Where
- Spain
- Volunteers
- 36,573 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Neoplasms
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
This randomised, double-blind phase III trial will be performed in patients with head and neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy and safety of afatinib (BIBW 2992) with…
- Trial name
- NCT01345669
- Testing
- Afatinib
- Where
- 162 sites in United States, Argentina and 27 more
- Volunteers
- 617 people
- Sponsor
- Boehringer Ingelheim
Ovarian Neoplasms, Peritoneal Neoplasms
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced…
- Trial name
- NCT01015118
- Testing
- Paclitaxel, BIBF 1120, Carboplatin
- Where
- 281 sites in United States, Australia and 20 more
- Volunteers
- 1,366 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
The primary objective of this trial is to evaluate the efficacy and safety of BI 6727 in patients with locally advanced, metastatic or recurrent urothelial cancer after failure of first line or adjuvant/neoadjuvant chemotherapy.
- Trial name
- NCT01023958
- Testing
- BI 6727, IV infusion
- Where
- 21 sites in United States, Taiwan
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
The primary objective of this trial is to investigate the bioequivalence of one fixed dose combination tablet of empagliflozin/linagliptin (Test, T) compared with the free combination of one empagliflozin tablet and one…
- Trial name
- NCT02758171
- Testing
- Empagliflozin, Linagliptin
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.